title: Role of the angiotensin II system in regulation of ovulation and blood flow in the rat ovary.
abstract: The aim of the present study was to examine the roles of the angiotensin II receptor subtypes, AT(1) and AT(2), in ovulation, and to evaluate the contribution of angiotensin II-mediated pathways in regulation of ovarian blood flow. The AT(1)-specific antagonist, losartan, was administered alone or in combination with the AT(2)-specific antagonist, PD123319, to preovulatory rat ovaries perfused in vitro. Losartan (100 micromol l(-1)) did not affect the number of ovulations, whereas the combination of losartan (100 micromol l(-1)) and PD123319 (10 micromol l(-1)) inhibited ovulation. The angiotensin II antagonists did not affect the ovarian production of oestradiol, progesterone, prostaglandin E(2) (PGE(2)), PGF(2 alpha) or plasminogen activator activity. Ovarian nitric oxide production was inhibited by losartan. Ovarian blood flow was measured by laser Doppler flowmetry in vivo in preovulatory rat ovaries. Intrabursal injection of angiotensin II reduced ovarian blood flow of gonadotrophin-stimulated rats. Losartan had no effect on basal ovarian blood flow but completely blocked the angiotensin II-induced reduction. In contrast, treatment with PD123319 increased basal ovarian blood flow and failed to reverse the effect of exogenously administered angiotensin II, indicating that under physiological conditions, ovarian blood flow of the rat is negatively regulated by angiotensin II mainly through the action of AT(2). Taken together, these results indicate that two different types of angiotensin II receptor facilitate ovulation by cooperative mechanisms and that they regulate ovarian blood flow in a different manner.
authors.affiliation: Department of Obstetrics and Gynecology, The Sahlgrenska Academy at Göteborg University, Göteborg, Sweden. ken_mitsube@hotmail.com
authors.forename: K
authors.initials: K
authors.lastname: Mitsube
authors.forename: M
authors.initials: M
authors.lastname: Mikuni
authors.forename: M
authors.initials: M
authors.lastname: Matousek
authors.forename: U
authors.initials: U
authors.lastname: Zackrisson
authors.forename: M
authors.initials: M
authors.lastname: Brännström
mesh_terms: D000804:Angiotensin II / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000502:physiology*; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D015232:Dinoprostone / Q000032:analysis; D004357:Drug Synergism; D005260:Female; D007093:Imidazoles / Q000494:pharmacology; D017078:Laser-Doppler Flowmetry; D019808:Losartan / Q000494:pharmacology*; D010053:Ovary / Q000098:blood supply* / Q000737:chemistry; D010060:Ovulation / Q000187:drug effects*; D010960:Plasminogen Activators / Q000032:analysis; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012039:Regional Blood Flow / Q000187:drug effects
chemical_list: D057911:Angiotensin Receptor Antagonists; D007093:Imidazoles; D011725:Pyridines; D000804:Angiotensin II; C073402:PD 123319; D010960:Plasminogen Activators; D019808:Losartan; D015232:Dinoprostone